There seems to be no need for Covaxin in the U.S. and there are no indications that the U.S. is considering approving it. Consequently, OCGN stock is worth shorting.
Ocugen Stock Is Left Behind As the U.S. Emerges From the Pandemic
2021-05-17T14:37:53-04:00May 17th, 2021|
Related Posts
-
How To Analyze 8%-Yielding Tech CEFs
May 21st, 2024 -
Nestlé Launching Frozen Food Brand For Ozempic Users
May 21st, 2024